Summary & Overview
HCPCS J9046: Bortezomib (Dr. Reddy's) Injection, 0.1 mg
HCPCS Level II code J9046 denotes a 0.1 mg unit of bortezomib (Dr. Reddy's), a parenteral oncology medication not therapeutically equivalent to J9041. Nationally, this code matters because it enables payers and providers to distinguish between manufacturers and formulations of a widely used proteasome inhibitor for hematologic malignancies, which can affect billing, inventory, and reimbursement pathways.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for bortezomib use, the service setting where charges typically occur (outpatient infusion centers, hospital outpatient departments, and physician offices), and the implications of manufacturer-specific HCPCS coding.
This publication provides benchmarks and billing guidance context where available, highlights typical sites of service for administration, and summarizes common modifiers and coding considerations relevant to J9046. It also identifies gaps where input data was not provided. The goal is to give billing managers, practice administrators, and policy analysts a clear, national-level reference for handling claims that involve this specific bortezomib formulation.
Billing Code Overview
HCPCS Level II code J9046 describes an injection of bortezomib (dr. reddy's), not therapeutically equivalent to J9041, in a 0.1 mg unit. The code represents a chemotherapy agent supplied for parenteral administration and is used when this specific manufacturer's formulation is billed separately.
Service Type: Chemotherapy drug administration (parenteral oncology medication)
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or physician office administration
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with relapsed multiple myeloma receives intravenous bortezomib (manufacturer: Dr. Reddy's) as part of a combination chemotherapy regimen in the outpatient oncology infusion clinic. The patient presents for cycle 3, day 1 of therapy with prior baseline labs reviewed (complete blood count, metabolic panel, liver function tests) and a pre-infusion assessment documenting performance status, neuropathy symptoms, and current medications. The oncology nurse prepares the dose based on body surface area and the physician verifies orders; the drug is administered via subcutaneous injection in the clinic with vital signs monitored before, during, and after the injection. The patient has an established plan for antiemetic and antiviral prophylaxis and returns for scheduled follow-up and laboratory monitoring to assess hematologic and neurologic toxicity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure is not a surgery | Use when reporting a non-surgical injectable drug administration when required by a payor that accepts 00 to indicate standard service. |
22 |